Semaglutide for Liver Health: What the Evidence Shows
What human and animal studies show about Semaglutide for liver health, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 305
- PubMed records, our ledger
- Animal studies
- 59
- PubMed records, our ledger
- Studies we summarised
- 2
- with an outcome for liver health
Evidence for liver health
Each row is an outcome related to liver health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Steatohepatitis resolution | Steatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide vs 34.3% on placebo. | Human RCTn = 1197 | The New England journal of medicine 2025, PMID 40305708 |
| Fibrosis reduction | Liver fibrosis was reduced without worsening steatohepatitis in 36.8% on semaglutide vs 22.4% on placebo. | Human RCTn = 1197 | The New England journal of medicine 2025, PMID 40305708 |
| NASH resolution | NASH resolved without worsening fibrosis in 59% at 0.4 mg vs 17% on placebo. | Human RCTn = 320 | The New England journal of medicine 2021, PMID 33185364 |
| Fibrosis stage improvement | Fibrosis improved in 43% at 0.4 mg vs 33% on placebo, not a significant difference (P = 0.48). | Human RCTn = 320 | The New England journal of medicine 2021, PMID 33185364 |
PubMed records for Semaglutide and liver health: 305 human, 59 animal (search counts, not studies we reviewed). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Fatty liver, MASH and where semaglutide fits
MedlinePlus says steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in the liver.[3]
The Wegovy label has a MASH indication, for noncirrhotic disease with moderate to advanced fibrosis, and notes it was granted under accelerated approval based on improvement of MASH and fibrosis.[4]
The label's MASH indication is for adults with stages F2 to F3 fibrosis.[4]
What the liver trials found
In the phase 3 MASH trial, steatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide against 34.3% on placebo.[1]
Reduced fibrosis without worsening steatohepatitis was seen in 36.8% on semaglutide against 22.4% on placebo.[1]
The earlier phase 2 trial showed NASH resolution in 59% at the highest dose against 17% on placebo, yet fibrosis improvement was not significantly different there.[2]
Safety to know
In the phase 2 liver trial nausea, constipation and vomiting were more common at the top dose than on placebo, and it reported malignant neoplasms in 3 treated patients and none on placebo.[2]
Other peptides people research for liver health
All peptides for liver health, comparedCommon questions
Does Semaglutide help with liver health?
The strongest study we summarise for liver health is human rct evidence, across 2 studies with an outcome for liver health. A trial result is not an approval; see the legal status.
Is Semaglutide approved for liver health?
Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Which conditions that approval covers is set by the label; use for anything else is off-label.
What is the best peptide for liver health?
There is no single answer. Our liver health overview compares each candidate by evidence grade and legal status rather than by popularity.
Is semaglutide approved for fatty liver?
Wegovy is approved, under accelerated approval, for noncirrhotic MASH with moderate to advanced fibrosis in adults.[4]
Does semaglutide reduce liver fat?
The cached trials report MASH histology rather than liver fat percentage; the phase 3 result is resolution of steatohepatitis in 62.9% on semaglutide versus 34.3% on placebo.[1]
More on Semaglutide
Sources
- 1Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 2A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.The New England journal of medicine · 2021PMID 33185364Accessed 2 Oct 2026
- 3medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
- 4WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.